- ROUNDTABLE: Pharmacy’s future in sync with technology
- Study from NCPA sheds new light on med synchronization programs
- Coalition of healthcare industry stakeholders address best practices regarding controlled substances
- Senate passes Drug Quality and Security Act
- EXPERT BLOG: Provider status for pharmacists — one way or another
WASHINGTON — A bill awaiting a signature or veto from New York governor Andrew Cuomo that would restrict home delivery of chronic medications has attracted criticism from the Federal Trade Commission and the pharmacy benefit manager lobby.
In a letter to New York state Sen. James Seward responding to the senator's request for comments, the FTC said New York Assembly Bill 5502-B would harm consumers and raise the prices of drugs while reducing access to them.
Seward's bill is intended to help patients choose how and where prescriptions are filled, but the FTC said it would limit a health plan's ability to steer beneficiaries to lower-cost mail-order vendors using financial incentives and other terms of coverage if a competing retail pharmacy is willing to fill prescriptions at "comparable prices."
"By restricting a health plan's ability to offer favorable treatment to a low-cost mail-order pharmacy, the bill undercuts pharmacies' incentives to bid aggressively for a share of that health plan's business," the letter read.
"The Federal Trade Commission's comments on the anti-mail-service pharmacy bill make it clear that it would harm consumers by limiting access and raising their prescription drug costs," Pharmaceutical Care Management Association president and CEO Mark Merritt said. "Governor Cuomo should veto this prescription drug tax on small business."